LEENO Industrial (058470) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
14 Jul, 2026Executive summary
Q1 2025 revenue was KRW 78.4 billion, with operating income of KRW 34.9 billion and net income of KRW 29.3 billion, reflecting strong profitability and stable operations.
The company specializes in semiconductor test sockets, probes, and medical device components, with 61.33% of Q1 sales from IC test sockets and 25.81% from probe pins.
Export sales dominate, accounting for over 76% of total revenue, with a robust global distribution network.
No borrowings were reported, maintaining a debt-to-equity ratio of 0%.
Financial highlights
Q1 2025 revenue: KRW 78.4 billion (down from KRW 278.2 billion for FY2024).
Operating income: KRW 34.9 billion; net income: KRW 29.3 billion.
Gross margin: 30.1% (KRW 23.6 billion gross profit on KRW 78.4 billion revenue).
Cash and cash equivalents at period end: KRW 86.9 billion.
Dividend payout ratio for recent years averages 40%.
Outlook and guidance
The company plans to maintain a dividend payout ratio of around 30% of net income, subject to business performance.
Ongoing investment in new factory construction (KRW 97.2 billion through 2026) to expand production and R&D capacity.
Anticipates continued growth in semiconductor and medical device markets, supported by global trends in AI, 5G, and healthcare.
Latest events from LEENO Industrial
- Global semiconductor test leader with strong financials, innovation, and major tech clients.058470
Investor presentation - H1 2026 net income reached KRW 106.32 billion on KRW 242.96 billion revenue, with zero debt.058470
Q2 2026 - Revenue and profit rose, margins remained high, and major expansion was funded internally.058470
Q4 2024 - H1 2025 net income was KRW 70.5B on KRW 190.9B revenue, with zero debt and robust exports.058470
Q2 2025 - H1 2024 net income margin exceeded 40% on ₩125.8B sales, with zero debt and strong exports.058470
Q2 2024 - Revenue and profit surged on strong semiconductor and medical device demand, with zero debt.058470
Q4 2025 - 2024 Q3 YTD revenue and profit fell, but zero debt and robust R&D support future growth.058470
Q3 2024 - Q1 2026 delivered robust growth, high profitability, and zero debt, with strong export sales.058470
Q1 2026 - Strong export-driven growth, high margins, and major factory investment with zero debt.058470
Q3 2025